ChemoCentryx, Inc.

ACTIVE

1 Amgen Center Dr, 加利福尼亚州圣马特奥县, California, United Stateswww.chemocentryx.comPublic178 employeesEstablished: 1997-01-01

Part of Amgen, Inc.

Clinical Trials

66 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1997

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

58.0%

Phase 2

1.4%

Trial Status Distribution

Active, not recruiting

95.7%

Completed

2.9%

Terminated

1.4%

Clinical Trials

Trials sponsored by this organization (69)

A Study To Determine The Safety, Tolerability, Pharmacokinetics And Recommended Phase 2 Dose Of CCX559 In patients With Solid Tumors

Phase 1

Terminated

interventional

Oct 202121 participants

A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of Vasculitis of a certain type, called ANCAAssociated Vasculitis (AAV).

Phase 1

Active, not recruiting

Jan 2021331 participants

A study to evaluate the efficacy og CCX140-B in patients with FSGS

Phase 1

Active, not recruiting

Nov 202040 participants

An open, dose escalation study in patients with Primary Focal Segmental Glomerulosclerosis (FSGS - a type of glomerular disease causes scarring in the kidney) and Nephrotic Syndrom (collection of symptoms due to kidney damage)

Phase 1

Active, not recruiting

Aug 201913 participants

A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of Vasculitis of a certain type, called ANCA-Associated Vasculitis (AAV).

Phase 1

Active, not recruiting

Jun 2018300 participants

A controlled study to evaluate the safety and efficacy of the study drug, CCX140-B, in subjects with Focal Segmental Glomerulosclerosis (a type of glomerular disease)

Phase 1

Active, not recruiting

May 201840 participants

A study in which the safety and efficacy of CCX140-B is compared with placebo in patients with Focal Segmental Glomerulosclerosis

Phase 1

Active, not recruiting

Mar 201840 participants

Study to determine the dose CCX140-B and to evaluate the its safety and efficacy of in Subjects with Focal Segmental Glomerulosclerosis (FSGS)

Phase 1

Active, not recruiting

Mar 201840 participants

Page 1 of 9

Approvals

Approvals by Agency

FDA

Food and Drug Administration

Approvals

Recent Approvals

News

No news articles found

Back to Organizations